MSCs have the potential to play a critical role in the study of regenerative medicine. Harvested from bone marrow, these multipotent cells were at the center of the world’s first tissue-engineered organ transplant in 2008 when surgeons in Spain successfully reconstructed a patient’s windpipe from her own stem cells. A key component for stem cell research to advance into clinical trials and beyond is the ability to put validated tools into the hands of researchers. Currently there are several MSC experimental treatments in phase 2 and 3 Investigational New Drug (IND) clinical trials. These trials are evaluating potential therapies, including: repairing heart tissue following a heart attack; a means to protect pancreatic islet cells in patients with Type I diabetes; and repairing lung tissue in patients with chronic obstructive pulmonary disease. MSCs’ immunosuppressant capabilities are also being investigated as a potential treatment for Crohn’s disease, an autoimmune condition, and neurological disorders resulting from stroke. As an FDA-cleared device, StemPro MSC SFM can potentially expedite the regulatory review process associated with investigational medical studies because it allows the reviewers to focus on the science rather than the manner in which the cells are grown.